Literature DB >> 19505418

[Laparoscopic intraperitoneal hyperthermic perfusion in palliation of malignant ascites. Case report].

L Graziosi1, W Bugiantella, E Cavazzoni, A Donini.   

Abstract

Malignant ascites is a pathological condition, due to several abdominal and extra-abdominal neoplasms, representing a difficult challenge in treatment. Different medical and surgical options have been proposed, but none of them have shown efficacy, leading only to partial and temporary relief of symptoms. Laparoscopic intraperitoneal chemotherapy may be a valid therapeutic option in patients in whom medical therapies have failed and peritoneovenous shunting is contraindicated. A 49-years old woman with malignant ascites, secondary to peritoneal localization of right pleural mesothelioma, underwent, after failure of medical therapy, laparoscopic intraperitoneal chemotherapy (with Cisplatin 25 mg/m2/L and Doxorubicin 7 mg/m2/L). An important and lasting reduction of ascites and abdominal symptoms was documented till the exitus, due to pulmonary embolism after 11 months. Laparoscopic intraperitoneal chemotherapy may be a good therapeutic option to palliative malignant ascites in patient not eligible for a radical cytoreductive treatment, but further investigations are needed to standardized dosage and perfusion procedure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19505418

Source DB:  PubMed          Journal:  G Chir        ISSN: 0391-9005


  2 in total

Review 1.  Malignant ascites: pathophysiology and treatment.

Authors:  Emanuel Cavazzoni; Walter Bugiantella; Luigina Graziosi; Maria Silvia Franceschini; Annibale Donini
Journal:  Int J Clin Oncol       Date:  2012-03-31       Impact factor: 3.402

2.  Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites.

Authors:  Reese W Randle; Katrina R Swett; Douglas S Swords; Perry Shen; John H Stewart; Edward A Levine; Konstantinos I Votanopoulos
Journal:  Ann Surg Oncol       Date:  2013-08-28       Impact factor: 5.344

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.